Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study

Digestion

Volumn 84, Issue 2, 2011, Pages 128-133

  Ishikawa, Hideki ^a,d   Matsumoto, Satoshi ^b   Ohashi, Yuji ^b   Imaoka, Akemi ^b   Setoyama, Hiromi ^b   Umesaki, Yoshinori ^b   Tanaka, Ryuichiro ^b   Otani, Toru ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d NONE   (Japan)

Author keywords

Bifidobacterium; Myeloperoxidase activity; Ulcerative colitis

Indexed keywords

GALACTOSE OLIGOSACCHARIDE; MESALAZINE; MYELOPEROXIDASE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID; SYNBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL COUNT; BIFIDOBACTERIUM; BIFIDOBACTERIUM BREVE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; HUMAN; LAVAGE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 79955109038     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000322977     Document Type: Article

References (26)

1. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A: Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999; 169: 195-207. (Pubitemid 29338733)
2. Mizoguchi A, Mizoguchi E, Bhan AK: Immune networks in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2003; 9: 246-259.
3. Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989; 66: 365-378.
4. Liaskovskii TM, Podgorskii VS: Assessment of probiotics according to the international organizations (FAO/WHO) (in German). Mikrobiol Z 2005; 67: 104-112.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546. (Pubitemid 41032360)
6. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623. (Pubitemid 39434105)
7. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 697-698.
8. Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003; 22: 56-63. (Pubitemid 36164458)
9. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, et al: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141. (Pubitemid 39657947)
10. Imaoka A, Shima T, Kato K, Mizuno S, Uehara T, Matsumoto S, Setoyama H, Hara T, Umesaki Y: Anti-inflammatory activity of probiotic Bifidobacterium : Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells. World J Gastroenterol 2008; 14: 2511-2516.
11. Matts SG: The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961; 30: 393-407.
12. Azuma R, Sato T: Culture collection with VL medium; in Iizuka H, Hasagawa H (eds): Proceedings of the first International Conference on Culture Collection. Tokyo, University of Tokyo Press, 1970, pp 493-505.
13. Tanaka R, Mutai M: Improved medium for selective isolation and enumeration of Bifidobacterium Appl Environ Microbiol 1980; 40: 866-869. (Pubitemid 11215926)
14. Kitajima H, SumidaY, Tanaka R, Yuki N, Takayama H, Fujimuma M: Early administration of Bifidobacterium breve to preterm infants: Randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 1997; 76:F101-F107.
15. Carlson M, Raab Y, Seveus L, Xu S, Hallgren R, Venge P: Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002; 50: 501-506. (Pubitemid 34638869)
16. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, Macfarlane GT: Synbiotic therapy ( Bifidobacterium longum /Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005; 54: 242-249. (Pubitemid 40139241)
17. Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y: Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007; 42: 1306-1311. (Pubitemid 47537077)
18. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G et al: Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
19. Watanabe T, Nishio H, Tanigawa T, Yamagami H, Okazaki H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Asahara T et al: Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: Involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297:G506-G513.
20. Matsumoto S, Watanabe N, Imaoka A, Okabe Y: Preventive effects of Bifidobacterium -and Lactobacillus -fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion 2001; 64: 92-99.
21. Helphingstine CJ, Hentges DJ, Campbell BJ, Butt J, Barrett JT: Antibodies detectable by counterimmunoelectrophoresis against Bacteroides antigens in serum of patients with inflammatory bowel disease. J Clin Microbiol 1979; 9: 373-378.
22. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T: Characterization of antibody responses against rectal mucosaassociated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000; 15: 61-68. (Pubitemid 30140928)
23. Onderdonk AB, Cisneros RL, Bronson RT: Enhancement of experimental ulcerative colitis by immunization with Bacteroides vulgatus Infect Immun 1983; 42: 783-788. (Pubitemid 14230280)
24. Onderdonk AB, Bronson R, Cisneros R: Comparison of Bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis. Infect Immun 1987; 55: 835-836.
25. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y: Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbe Infect 2003; 5: 115-122.
26. Sina C, Gavrilova O, Forster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, Rehmann A, et al: G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 2009; 183: 7514-7522.